![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Watmind USA COVID-19 Test Gets Emergency Use Authorization
Watmind USA COVID-19 Test Gets Emergency Use Authorization
The FDA has granted Emergency Use Authorization (EUA) to Watmind USA’s Speedy Swab rapid COVID-19 antigen self-test for non-prescription home use.
The immunoassay detects antigens from SARS-CoV-2 in individuals with symptoms of COVID-19 within the first six days of symptom onset, or individuals without symptoms or other epidemiological reasons to suspect COVID-19.
The lateral flow test, which uses anterior nasal swabs, must be administered twice over three days with 24-48 hours between tests.
The FDA said that all negative results “should be treated as presumptive,” adding that confirmation with a molecular assay may be necessary if there is a high likelihood of SARS-CoV-2 infection, such as in an individual with a close contact with COVID-19 or in communities with a high prevalence of infection.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct